Have any questions? 706-721-6582 or cts@augusta.edu
- OASIS: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisomeŽ followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species
Clinical Trial
OASIS: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisomeŽ followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species
This study aims to compare all-cause mortality at Day 42 following teatment with olorofim versus treatment with AmBisome followed by standard of care in the intent-to-treat population of patients with IFD caused by proven invasive aspergillosis at any site or probable lower respiratory tract disease Aspergillus species.
- Respiratory System
- AmBisome
- Fungal Infection
- IA
- IFD
- Invasive Aspergillous
- Invasive Fungal Disease
- Olorofim
Eligibility Criteria
- Inclusion Criteria Adult patients >18 years old with proven invasive aspergillosis requiring antifungal treatment AmBisome is an appropriate therapy for the patient Exclulsion Criteria Patients receiving supportive care due to predicted short survival time No current or prior medical history prohibited by protocol Consumption (current or historical use) of protocol prohibited medications
RESEARCH. INNOVATION. DISCOVERY.